{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-271609","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2024-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.460791+00:00","generated_at":"2026-05-29T07:20:35.120155+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"high","headline":"Inhibikase terminates unused ATM facility; no impact on capital","bullets":["Terminated ATM agreement with H.C. Wainwright effective Dec 11, 2024.","Original ATM limit was $5.66M; only $849k sold before reduction to $50k.","No shares sold under ATM since May 20, 2024.","Termination ends ability to issue equity at market via this facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-271609","json":"https://secwatch.observer/filing/0001193125-24-271609.json","markdown":"https://secwatch.observer/filing/0001193125-24-271609.md","text":"https://secwatch.observer/filing/0001193125-24-271609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524271609/0001193125-24-271609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524271609/d914736d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T07:20:35.120155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}